Beam Therapeutics Inc. (BEAM) Stock Score, Valuation & Financial Research
Beam Therapeutics Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 22/100.
Quick answer for BEAM
Beam Therapeutics Inc. currently has a Wall Street Score of 22/100. The stored market price is $23.99. Its financial score is 25/100. Its valuation score is 0/100. The latest WSS change is +0.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What Beam Therapeutics Inc. does
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin def
BEAM financial snapshot
- Wall Street Score:
- 22/100
- Current price:
- $23.99
- Market capitalization:
- $2.47B
- Revenue:
- $156.0M
- Net income:
- $-85.4M
- Free cash flow:
- $-360.0M
- Cash:
- $219.8M
- Total debt:
- $247.4M
- EPS:
- -0.82
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 12/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $-360.0M, showing cash burn in the current stored period.
- The balance sheet shows $219.8M of cash versus $247.4M of total debt, so leverage deserves attention.
- The latest Wall Street Score change is +0.1 points: BEAM increased 0.1 points because overall fundamentals improved.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-09.
How to research BEAM
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.